The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 411/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, V W, X, Y, and Z are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental heal disease or disorder.
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, V W, X, Y, and Z are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental heal disease or disorder.
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Pharmaceutical compositions including R-MDMA salts O-Methyl Mandelate Form A, Nitrate Form A, and Mandelate Form B exhibit properties that are favorable for a pharmaceutical active ingredient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.
Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
The present disclosure relates to methods of treating an anxiety disorder, including social anxiety disorder, comprising administering a composition comprising an enantiomerically enriched form of R(−)-MDMA.
The present disclosure relates to methods of treating an anxiety disorder, including social anxiety disorder, comprising administering a composition comprising an enantiomerically enriched form of R(-)-MDMA.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
Provided herein are carbamothioate and carbamodithioate derivates of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.
Provided herein are carbamothioate and carbamodithioate derivatives of 3,4-methylenedioxymethamphetamine (MDMA), and its stereoisomers (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine, and pharmaceutical compositions thereof, as well as a high purity process for the preparation of the parent compounds, wherein MDMA is a synthetic drug possessing both stimulant and mild hallucinogenic properties. Such derivatives could be used for treating or preventing a disease, disorder, or condition in which an increased level of 3,4-methylenedioxymethamphetamine is beneficial.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 317/48 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
C07D 317/58 - Radicals substituted by nitrogen atoms
The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 411/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed are pharmaceutical compositions and formulations of enantiomerically enriched or pure 3,4-methylenedioxymethamphetamine (MDMA) and methods for modulating aggression response behaviors that may be associated with a disorder and/or disease.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
Provided herein are compounds of Formula (I) and Formula (II), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental disease or disorder.
Provided herein are compounds of Formula (I) and Formula (II), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental disease or disorder.
C07D 305/00 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
14.
COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA
Compositions and kits comprising enantiomerically enriched forms of MDMA, an inhibitor of CYP2D6, and a pharmaceutically acceptable carrier. Also disclosed are methods of increasing or prolonging exposure of R(−)-MDA in plasma or brain of a subject in need thereof.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (II), e.g., in the treatment of a mental health disease or disorder.
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
16.
HETEROCYCLIC PROPYL AMINE MODULATORS OF MONOAMINERGIC TRANSPORTERS
123455, V, W, X, Y, and Z are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental heal disease or disorder.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
Pharmaceutical compositions including R-MDMA salts O-Methyl Mandelate Form A, Nitrate Form A, and Mandelate Form B exhibit properties that are favorable for a pharmaceutical active ingredient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
Provided herein is a process for the preparation of 3,4-methylenedioxyamphetamine, (R)-3,4-methylenedioxyamphetamine and (S)-3,4-methylenedioxyamphetamine.
C07D 317/08 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
C07D 317/44 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
C07D 317/46 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 317/48 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
20.
USE OF MDMA FOR TREATMENT OF STRESS-RELATED DISORDERS
Methods of treating a stress-related disease or disorder such as PTSD, decreasing side effects of 3,4-methylenedioxy-methamphetamine (MDMA), inducing neurite outgrowth, inducing structural neuroplasticity, or increasing brain-derived neurotrophic factor (BDNF) levels, comprising administering to a subject effective amounts of a composition comprising R(−)-3,4-methylenedioxymethamphetamine (R(−)-MDMA) are disclosed. Also disclosed are pharmaceutical compositions comprising R(−)-MDMA and a pharmaceutically acceptable carrier.
The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 411/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
24.
PREPARATION OF OPTICALLY ACTIVE ENANTIOMERS OF PIPERONYL AMINES BY RESOLUTION OF THE DIASTEREOMERIC SALTS
Provided herein is a process for resolving the (S)- and (R)- enantiomers of a compound of Formula (I), wherein L, R1, and R2 are defined herein.
Provided herein is a process for resolving the (S)- and (R)- enantiomers of a compound of Formula (I), wherein L, R1, and R2 are defined herein.
C07D 317/06 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
25.
Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
Provided herein is a process for the preparation of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.
The present disclosure provides compositions comprising (R)-MDMA or a pharmaceutically acceptable salt thereof with no or substantially no (S)-MDMA, pharmaceutically acceptable salt thereof, or metabolite thereof. Also provided herein are methods of using the compositions for treating diseases/disorders, e.g., PTSD.
Provided herein is a process for the preparation of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.
patents
